Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAGE: Efgartigimod in Elderly With Generalized Myasthenia Gravis
NCT07072988Phase 4Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Change from baseline in the mean dose of corticosteroids at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07072988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072988.